✦ LIBER ✦

PDG11: HEALTH AND ECONOMIC OUTCOMES OF A NEW ORAL DIABETES DRUG, PIOGLITAZONE (ACTOS*NF, TAKEDA), IN THE MANAGEMENT OF TYPE 2 DIABETES MELLITUS IN NORWAY

✍ Scribed by A Brandt; K Frislid; R Jansen; N Maniadakis; A Kielhorn

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PDG14: AN ASSESSMENT OF THE COSTEFFECTIV

✍ R Jansen; JO Clausen; N Maniadakis; A Kielhorn; A Brandt 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 66 KB

PDG6: COST-EFFECTIVENESS OF PIOGLITAZONE

✍ F Henriksson; A Brandt; L Thomander; A Kielhorn; R Jansen; N Maniadakis 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 52 KB

PDG1: THE OUTCOMES OF LONG-TERM TREATMEN

✍ N Maniadakis; A Kielhorn; K Heikkinen; A Brandt; R Jansen 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 53 KB

PDG3: AN ECONOMIC EVALUATION OF COMBINAT

✍ N Maniadakis; J Sacristan; J Reviriego; W Hart; R Jansen; A Kielhorn; A Brandt 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 55 KB

A retrospective cohort study of economic

✍ Richard A. Hansen; Joel F. Farley; Marcus Droege; Matthew L. Maciejewski 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 136 KB